Article Text

PDF
Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1
  1. J J Swensen1,
  2. J Keyser2,
  3. C M Coffin3,
  4. J A Biegel4,
  5. D H Viskochil5,
  6. M S Williams6
  1. 1
    ARUP Laboratories and Department of Pathology, University of Utah, Salt Lake City, Utah, USA
  2. 2
    Intermountain Healthcare Budge Clinic, Logan, Utah, USA
  3. 3
    Department of Pathology, Primary Children’s Medical Center and University of Utah, Salt Lake City, Utah, USA
  4. 4
    Department of Pediatrics, Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  5. 5
    Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA
  6. 6
    Intermountain Healthcare Clinical Genetics Institute, Salt Lake City, Utah, USA
  1. Dr J J Swensen, ARUP Laboratories, 500 Chipeta Way, Salt Lake City, Utah 84108, USA; jeffrey.swensen{at}aruplab.com

Abstract

Background: The role of germline and somatic SMARCB1 gene mutations in malignant rhabdoid tumour (MRT) predisposition is well known. Germline SMARCB1 mutations have also recently been identified in a subset of individuals with schwannomatosis. Surprisingly, MRT predisposition and schwannomatosis have never been reported to co-occur in a family. The correlation between genotype and phenotype for mutations in SMARCB1 has not been determined.

Results: We have identified a germline 2631 bp duplication that includes exon 6 of SMARCB1 in a unique family with a four generation history of MRT predisposition and schwannomatosis. This duplication segregates with disease in individuals affected with both conditions, linking MRT predisposition and schwannomatosis as components of the same syndrome in this family.

Conclusion: The unique combination of tumours that result from the duplication described in this report may provide important clues about the mechanisms that influence the phenotype associated with a given SMARCB1 mutation.

Statistics from Altmetric.com

Footnotes

  • Funding: This work was supported in part by a grant from the NIH (CA46274) to JAB.

  • Competing interests: None.

  • Ethics approval: The University of Utah Clinical Genetics Research Program was approved by the University of Utah Institutional Review Board

  • Patient consent: Obtained.

  • CMC’s present affiliation: Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.